Costs & Coping
Durvalumab maintains NSCLC patient-reported outcomes
Durvalumab provides clinically meaningful improvements in non–small cell lung cancer (NSCLC) without diminishing patient-reported outcomes (PROs), based on data from the phase 3 PACIFIC trial.
Continued smoking with cancer poses significant economic burden
Continued smoking by patients with cancer increases the risk of cancer treatment failure and leads to more than $10,000 of additional costs per patient
Financial toxicity high for lung cancer patients
When making decisions about lung cancer treatment, a patient’s finances frequently affects the care route they choose, said Leah Backhus, MD, chief of thoracic surgery at VA Palo Alto in Stanford, Calif.
Cost And Coping
Diagnosis and Therapy